| Followers | 128 |
| Posts | 2150 |
| Boards Moderated | 1 |
| Alias Born | 12/27/2007 |
Tuesday, April 29, 2014 3:02:39 PM
Look who joins the Board of Adherex ...And we have a SC 13 G/A filing see below ..Looking great here
http://finance.yahoo.com/news/adherex-appoints-two-independent-directors-120000064.html
About Dr. Khalid Islam
Dr. Khalid Islam has been the Chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led the transition from a loss-making to a cash-flow positive and profitable company. Under his leadership, the company value increased from US$25 million leading to a successful all cash US$1 billion merger with Jazz Pharmaceuticals, plc. From 1999-2008, Dr. Islam was President and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised US$300 million in the IPO and follow-ons. From 1987-1999, he held various positions in HMR & MMD (now Sanofi-Aventis). From 1977-1987, Dr. Islam worked in academia at Imperial College (Univ. of London) and in Milan University, where he was a contract professor. Dr. Islam is a graduate of Chelsea College and received his Ph.D. from Imperial College, University of London. He holds several patents and has published over 80 articles in leading journals.
SC 13 G/A 24.4.2014
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001013594-14-000386.txt&FilePath=\2014\04\24\&CoName=ADHEREX+TECHNOLOGIES+INC&FormType=SC+13G%2FA&RcvdDate=4%2F24%2F2014&pdf=
http://finance.yahoo.com/news/adherex-appoints-two-independent-directors-120000064.html
About Dr. Khalid Islam
Dr. Khalid Islam has been the Chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led the transition from a loss-making to a cash-flow positive and profitable company. Under his leadership, the company value increased from US$25 million leading to a successful all cash US$1 billion merger with Jazz Pharmaceuticals, plc. From 1999-2008, Dr. Islam was President and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised US$300 million in the IPO and follow-ons. From 1987-1999, he held various positions in HMR & MMD (now Sanofi-Aventis). From 1977-1987, Dr. Islam worked in academia at Imperial College (Univ. of London) and in Milan University, where he was a contract professor. Dr. Islam is a graduate of Chelsea College and received his Ph.D. from Imperial College, University of London. He holds several patents and has published over 80 articles in leading journals.
SC 13 G/A 24.4.2014
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001013594-14-000386.txt&FilePath=\2014\04\24\&CoName=ADHEREX+TECHNOLOGIES+INC&FormType=SC+13G%2FA&RcvdDate=4%2F24%2F2014&pdf=
Recent FENC News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 02:58:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:24:42 PM
- Fennec Pharmaceuticals Shares Rise After Earnings and Revenue Beat Forecasts (FENC) • IH Market News • 05/14/2026 12:47:47 PM
- Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2026 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 09:00:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:46:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:09:04 PM
- Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:27:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:05:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:05:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:38:18 PM
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/31/2026 10:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 08:44:02 PM
